ClinicalTrialsFinder
RecruitingNot ApplicableNCT07039370

Molecular Signatures of TMS Response in Treatment-Resistant Depression

The Relationship Between Plasma Metabolomics and Proteomics Profiling and Response to Transcranial Magnetic Stimulation Therapy in Treatment-Resistant Depression

Sponsor

Gulhane Training and Research Hospital

Enrollment

55 participants

Start Date

Jun 15, 2025

Study Type

INTERVENTIONAL

Conditions

Major Depression Disorder

Summary

Transcranial Magnetic Stimulation (TMS) therapy is an approved and effective treatment option for treatment-resistant depression (TRD). This study aims to identify biomarkers that predict TMS treatment response in TRD, provide insights into the neurobiological mechanisms underlying TMS efficacy, and contribute to personalized treatment strategies. By establishing proteomic and metabolomic signatures, this research seeks to enhance clinical decision-making, reduce healthcare costs, and improve patient outcomes in TRD. The findings will align with the precision medicine movement in psychiatry, advancing biomarker-driven therapeutic approaches for treatment-resistant depression.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study uses blood tests and brain scans to find biological markers that predict whether transcranial magnetic stimulation (TMS) — a non-invasive brain treatment using magnetic pulses — will work for people with treatment-resistant depression. **You may be eligible if...** - You have a diagnosis of major depressive disorder (MDD) - You have not responded adequately to at least two different antidepressant medications taken at proper doses - You are scheduled to receive TMS treatment - You are willing to provide blood samples and undergo brain imaging **You may NOT be eligible if...** - You have metal implants in your head that are incompatible with TMS - Your depression is caused by a medical condition like thyroid disease - You have a history of seizures or epilepsy Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICETMS

Transcranial Magnetic Stimulation (TMS) is a non-invasive brain stimulation technique approved for the treatment of major depressive disorder (MDD), particularly in individuals with treatment-resistant depression (TRD). TMS targets the left dorsolateral prefrontal cortex (DLPFC), a brain region often underactive in depression, and modulates neural activity through magnetic pulses. This study aims to evaluate the effects of TMS on plasma proteomic and metabolomic profiles in patients with TRD. Participants will undergo 20 sessions of intermittent theta burst stimulation (iTBS) over four weeks. Blood samples will be collected before and after treatment to identify molecular changes associated with clinical response. Healthy controls will provide single-time-point blood samples for baseline comparison. Findings may support the development of biomarker-based strategies for personalized treatment in psychiatry.

Locations(2)

Gulhane Training and Research Hospital

Ankara, Ankara, Turkey (Türkiye)

Gulhane Training and Research Hospital

Ankara, Ankara, Turkey (Türkiye)

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07039370

Related Trials

Home tDCS for the Treatment of Major Depression.

NCT075108803 locations

Neuromodulation and Attention Deficits in MDD

NCT071111691 location

The OBSERVE Protocol

NCT067252776 locations

Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans

NCT066719771 location